Open AccessRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine
Author(s) -
Albert Mwafongo,
Kondwani Nkanaunena,
Yu Zheng,
Evelyn Hogg,
Wadzanai Samaneka,
Lloyd Mulenga,
Abraham Siika,
Judith S. Currier,
Shahin Lockman,
Michael D. Hughes,
Mina C. Hosseinipour
Publication year - 2014
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000202
Subject(s) - nevirapine , lopinavir , medicine , renal function , creatinine , emtricitabine , nephrotoxicity , odds ratio , ritonavir , confidence interval , urology , gastroenterology , kidney , viral load , human immunodeficiency virus (hiv) , virology , antiretroviral therapy
Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration with boosted protease inhibitors, which increases its exposure, may further increase the risk of renal insufficiency.